Merck Revives Spat With Teva Over Fosamax

Law360, New York (May 11, 2006, 12:00 AM EDT) -- In a long-simmering patent dispute over blockbuster osteoporosis drug Fosamax, Merck & Co. is striking back at Israeli generic maker Teva Pharmaceuticals, saying Teva garnered a Federal Circuit victory last year by withholding one of its own patent applications in a move Merck is calling a “grave miscarriage of justice.”

The U.S. Court of Appeals for the Federal Circuit ruling, handed down in January 2005, held that the patent on the once-weekly osteoporosis drug Fosamax, U.S. Patent No. 5,994,329, would expire in February 2008, a decade...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.